ADHD
54 programs · 53 companies
Programs
54
Companies
53
Trials
40
MOAs
38
FGFRiMALT1iUSP1iPRMT5iBTKiIL-13iCGRPantFcRniSTINGagCAR-T CD19
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Phase 3 | C5 | ||
| ABB-8985 | Phase 2 | CD20 | ||
| SNY-2934 | Phase 3 | KRASG12D | ||
| Talainavolisib | Preclinical | KRASG12D | ||
| Zanumavacamten | Phase 2/3 | TROP-2 | ||
| Ribozanubrutinib | Phase 1 | CDK4/6 | ||
| INC-2432 | Phase 2 | CD47 | ||
| Zanufutibatinib | NDA/BLA | CD38 | ||
| Doxalemzoparlimab | Approved | AHR | ||
| EDI-3618 | NDA/BLA | FXIa | ||
| CVA-2171 | Phase 1/2 | LAG-3 | ||
| ARC-1235 | Phase 3 | GPRC5D | ||
| EXA-4696 | Phase 2/3 | KRASG12C | ||
| 452-2449 | Preclinical | JAK1 | ||
| RDY-8710 | Approved | CD38 | ||
| MEM-IIT-110 | Phase 1/2 | WRN | ||
| Capivorutinib | Phase 2 | IL-17A | ||
| Olpazasiran | Preclinical | DLL3 | ||
| ABL-5779 | Phase 1/2 | WRN | ||
| Rimatinib | NDA/BLA | VEGF | ||
| ELE-7041 | Preclinical | Menin | ||
| Capitapinarof | Phase 3 | EZH2 | ||
| Datovorutinib | Approved | PRMT5 | ||
| Suraderotide | Phase 1 | TIGIT | ||
| Kematenlimab | Phase 3 | FGFR | ||
| PRO-7290 | Phase 2/3 | B7-H3 | ||
| Mirinaritide | Phase 2/3 | Cl18.2 | ||
| 208-7575 | Phase 2/3 | VEGF | ||
| AJA-7822 | Phase 2 | IL-23 | ||
| NVE-9059 | Approved | IL-23 | ||
| RYT-3886 | Phase 2/3 | Cl18.2 | ||
| Teraglumide | Phase 2 | BCMA | ||
| 451-4283 | Phase 2 | C5 | ||
| 219-5261 | Phase 3 | Tau | ||
| Mavulemzoparlimab | Phase 3 | FXIa | ||
| KIA-7048 | Phase 3 | SHP2 | ||
| Olpazasiran | Phase 3 | FcRn | ||
| Doxabrutinib | Phase 2/3 | FcRn | ||
| 417-3039 | Phase 2 | SHP2 | ||
| Zanutinib | Approved | LAG-3 | ||
| Zoritinib | Approved | PLK4 | ||
| ESC-2069 | Phase 1/2 | FGFR | ||
| Motaderotide | Phase 2 | C5 | ||
| Pexavorutinib | Phase 1/2 | Nectin-4 | ||
| Ivoinavolisib | Phase 2/3 | CFTR | ||
| KAR-IIT-216 | Phase 1 | Menin | ||
| CAN-IIT-252 | Phase 3 | B7-H3 | ||
| 300-8538 | NDA/BLA | PLK4 | ||
| 600-3422 | Phase 1 | KRASG12D | ||
| BRK-7538 | Phase 2/3 | DLL3 | ||
| ZTS-4049 | Phase 2 | Nectin-4 | ||
| ZTS-9629 | Phase 3 | CFTR | ||
| Doxabrutinib | Phase 2 | Nectin-4 | ||
| VEE-457 | Phase 1 | BCL-2 |
Trials (40)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04076949 | SNY-2934 | Phase 3 | Recruiting |
| NCT08146255 | SNY-2934 | Phase 3 | Completed |
| NCT03415788 | SNY-2934 | Phase 3 | Terminated |
| NCT05574929 | Talainavolisib | Preclinical | Recruiting |
| NCT04933373 | Ribozanubrutinib | Phase 1 | Not yet recr... |
| NCT03887413 | ARC-1235 | Phase 3 | Terminated |
| NCT04749201 | ARC-1235 | Phase 3 | Recruiting |
| NCT03304152 | EXA-4696 | Phase 2/3 | Completed |
| NCT05029932 | RDY-8710 | Approved | Recruiting |
| NCT06044038 | MEM-IIT-110 | Phase 1/2 | Recruiting |
| NCT03381197 | Capivorutinib | Phase 2 | Terminated |
| NCT03662801 | Capivorutinib | Phase 2 | Recruiting |
| NCT04972712 | ABL-5779 | Phase 1/2 | Completed |
| NCT05024244 | Rimatinib | NDA/BLA | Completed |
| NCT07256886 | Rimatinib | NDA/BLA | Not yet recr... |
| NCT06901930 | ELE-7041 | Preclinical | Completed |
| NCT05178352 | Capitapinarof | Phase 3 | Terminated |
| NCT04768525 | Capitapinarof | Phase 3 | Completed |
| NCT07326952 | Datovorutinib | Approved | Terminated |
| NCT04500037 | Datovorutinib | Approved | Terminated |